Calciphylaxis is a rare but devastating disorder most commonly observed in patients with end-stage renal disease, although it does occasionally develop in patients with acute renal failure, normal renal function, or earlier stages of chronic kidney disease (non-uremic calciphylaxis). Also known as calcific uremic arteriolopathy, it is characterized by painful skin lesions caused by cutaneous arteriolar calcification leading to tissue ischemia and infarction. Calciphylaxis is associated with substantial morbidity due to severe pain, nonhealing wounds, and frequent hospitalizations. It is a highly fatal condition with 1-year mortality rates greater than 50%, most often due to sepsis.
Risk Factors for Calciphylaxis
Risk factors and associations for calciphylaxis include the following:
Abnormalities of the Chronic Kidney Disease-Bone Mineral Disease Axis
Although calciphylaxis can develop in the absence of kidney disease, most cases occur in patients with advanced renal failure. The incidence of calciphylaxis in dialysis patients ranges from 0.04% to 4%, and the rate appears to be rising over the last decade.
Calciphylaxis typically results from calcification of the medial layer of arterioles and small arteries. Blood flow is further reduced by endothelial injury and formation of microthrombi leading to luminal narrowing and occlusion. These changes cause tissue ischemia, necrosis, and ulceration.
The cause and mechanisms leading to calciphylaxis remain poorly understood, and its development is likely dependent on multiple factors that lead to medial calcification of arterioles. Elevated calcium x phosphate product, increased parathyroid hormone levels, and administration of activated vitamin D have been associated with the development of calciphylaxis. However, abnormalities of bone-mineral parameters such as these are typically not sufficient to cause calciphylaxis on their own in most patients. Disturbances in bone-mineral parameters are extremely common in dialysis patients. However, most do not develop calciphylaxis. Further, calciphylaxis may develop even if parathyroid hormone, phosphorus, and calcium levels are normal.
Deficiency of vascular calcification inhibitors such as fetuin-A, osteoprotegerin, and matrix G1a protein may play a role in the development of calciphylaxis. Fetuin-A is a glycoprotein that binds calcium and phosphorus and may help to prevent calcification of vessels and soft tissue. Fetuin-A is downregulated in dialysis patients. Matrix G1a protein may also prevent vascular calcification and is dependent on vitamin K dependent carboxylation for its activity. Warfarin use has been implicated as a risk factor for calciphylaxis, which may be related to its interference with vitamin K dependent activation of matrix G1a.
Biopsy of the affected skin is needed to make the diagnosis of calciphylaxis. Both dermis and epidermis are often ulcerated and necrotic with various secondary changes. Calcification of small to medium sized blood vessles is seen. The intimal layer of blood vessels id most commonly fibrosed and intravascular thrombi may be seen. The characterstic feature is the diffuse calcification of small capillaries in the adipose tissue.
Calciphylaxis typically presents with extremely painful ischemic cutaneous lesions or painful subcutaneous nodules without skin changes, although at times, pain may precede the development of the lesions. Skin lesions often appear as violaceous or erythematous subcutaneous nodules and plaques. Livedo reticularis can also result from ischemia. As the lesions progress, they may become ulcerated with the development of necrosis, eschar, and infection. Proximal areas with increased adipose tissue such as the abdomen, thighs, and buttocks are most commonly involved, although distal sites such as the digits can also be affected. Extreme pain is a hallmark of calciphylaxis leading to considerable morbidity.
While skin manifestations are dominant, calciphylaxis is a systemic condition that may involve other organs including the eyes, penis, muscle, brain, intestines, and lungs.
Diagnosing calciphylaxis requires a high index of suspicion. A definitive diagnosis is made after a skin biopsy of one of the lesions. The histologic evaluation shows medial calcification of dermal arterioles or small arteries and may show fibrointimal hyperplasia, microthrombi, and vascular narrowing or occlusion, often with evidence of necrosis.
The need for biopsy in the diagnosis of calciphylaxis is debatable. While a biopsy is often performed to differentiate early stages of calciphylaxis from other skin lesions, the biopsy itself carries some risk, particularly for patients with only subcutaneous nodules. A skin punch biopsy may precipitate ulceration, bleeding, infection, or necrosis. Thus, if the clinical suspicion for calciphylaxis is high, some clinicians will forego a biopsy and treat based on a presumptive diagnosis.
Laboratory workup should include a metabolic panel, hepatic function, partial thromboplastin time, international normalized ratio, and albumin tests. In some cases, a hypercoagulable workup may be appropriate.
Additional experimental diagnostic tools include using nuclear bone scans to evaluate for soft tissue calcification in the areas of the lesions. Assessing circulating fetuin-A levels has also been suggested as an approach to evaluating for calciphylaxis.
No prospective trials have assessed treatment efficacy in patients with calciphylaxis. Evidence of successful interventions predominantly derives from case reports, case series, and retrospective analyses. Lesions are challenging to treat and are often refractory to isolated therapies. Therefore, a multidisciplinary and multimodal approach should be employed. A calciphylaxis team approach may include input from a nephrologist, dermatologist, dietician, wound surgeon, wound nurse, pain management specialist, palliative care team, and hyperbaric oxygen provider.
Given the possible role of bone-mineral disorders in the pathophysiology of calciphylaxis, careful attention should be paid to avoid hypercalcemia, with phosphorus levels maintained at less than 5.5 mg/dL. At a minimum, dialysis adequacy criteria should be met, and dialysis frequency can be increased if necessary to optimize the clearance of uremic molecules and improve bone-mineral markers. Patients should discontinue the use of calcium supplements, and calcium-based phosphate binders should be converted to non-calcium containing binders. High calcium dialysate baths (greater than 2.5 meq/L) should also be avoided. Parathyroid hormone should be maintained between 150-300 ng/mL. For patients with secondary hyperparathyroidism, cinacalcet, a calcimimetic agent used to lower parathyroid hormone, should be used in place of activated vitamin D to avoid increasing serum calcium and phosphorus levels. In the evaluation of cinacalcet hydrochloride therapy to lower cardiovascular events (EVOLVE) trial, dialysis patients with secondary hyperparathyroidism were randomized to cinacalcet or placebo, and those who received cinacalcet were found to be less likely to develop calciphylaxis, although the overall incidence was low in both groups. Etelcalcetide, a new intravenous calcimimetic, has not been studied in calciphylaxis but may be a reasonable alternative in patients intolerant of cinacalcet. The role of surgical parathyroidectomy in the treatment of calciphylaxis has not been established.
In addition to addressing bone mineral parameters, the patient should discontinue any potentially problematic medications if possible. Given the association between warfarin and calciphylaxis, patient education regarding the risks and benefits of stopping anticoagulation or switching to a direct acting oral anticoagulant is important. Studies regarding the use of vitamin K supplementation to activate matrix G1a protein have been proposed to study vitamin K as a possible treatment option for calciphylaxis, but the efficacy of this approach has not been evaluated.
Sodium thiosulfate is now routinely used off-label in the treatment of calciphylaxis. In a case series evaluating the efficacy of sodium thiosulfate, more than 70% of patients receiving it had improvement or resolution of their skin lesions, and mortality rate was lower than historically published data. Sodium thiosulfate is typically given intravenously during hemodialysis, but the use of oral and intralesional delivery is being investigated. The mechanism by which sodium thiosulfate treats calcific uremic arteriolopathy remains unknown. Previously, it was believed to work through calcium chelation, however recent studies suggest that sodium thiosulfate may inhibit soft tissue calcification through mechanisms independent of calcium binding. Side effects of sodium thiosulfate include metabolic acidosis and fluid overload.
Wound care and pain management are important. Debridement may be needed to remove devitalized and necrotic tissue, prevent infection, and promote healing. Prophylactic antibiotics are not recommended. However, wounds often become infected, and clinicians should have a low threshold to start antibiotics. Recent reports suggest a possible role of hyperbaric oxygen therapy which has been shown to facilitate wound healing in some patients.
Reports have indicated improvement or complete resolution of calciphylaxis lesions following kidney transplantation in patients with end-stage renal disease. However, calciphylaxis can develop after transplantation as well, and the immunosuppression medications used in transplantation may increase the risks of developing infections within the skin lesions.
The differential diagnosis for calciphylaxis includes warfarin skin necrosis, antiphospholipid syndrome, cholesterol embolization, vasculitis, cellulitis, and atherosclerosis. The history, findings on physical examination, laboratory testing, and histologic assessment can differentiate calciphylaxis from other entities.
Calciphylaxis has a poor prognosis with 1-year mortality rates between 45% and 80%, and the response to therapy is also poor. Patients with ulcerated lesions are particularly prone to developing an infection, which is the leading cause of death.
Clinicians should have a high index of suspicion for calciphylaxis in a patient with end-stage renal disease who presents with painful skin lesions. Calciphylaxis is a devastating disease with high rates of morbidity and mortality. A definitive diagnosis for calciphylaxis is made with a skin biopsy which predominantly shows arteriolar medial layer calcification, although the diagnosis can at times be made on clinical grounds. Some medications have been implicated as risk factors for calciphylaxis, and a patient's medication list must be carefully scrutinized if calciphylaxis develops. Treatment of calciphylaxis requires a multidisciplinary approach.
|||Association Between Hypercoagulable Conditions and Calciphylaxis in Patients With Renal Disease: A Case-Control Study., Dobry AS,Ko LN,St John J,Sloan JM,Nigwekar S,Kroshinsky D,, JAMA dermatology, 2018 Feb 1 [PubMed PMID: 29238798]|
|||Calciphylaxis: risk factors, diagnosis, and treatment., Nigwekar SU,Kroshinsky D,Nazarian RM,Goverman J,Malhotra R,Jackson VA,Kamdar MM,Steele DJ,Thadhani RI,, American journal of kidney diseases : the official journal of the National Kidney Foundation, 2015 Jul [PubMed PMID: 25960299]|
|||The Effect of Cinacalcet on Calcific Uremic Arteriolopathy Events in Patients Receiving Hemodialysis: The EVOLVE Trial., Floege J,Kubo Y,Floege A,Chertow GM,Parfrey PS,, Clinical journal of the American Society of Nephrology : CJASN, 2015 May 7 [PubMed PMID: 25887067]|
|||Multidisciplinary approach to calcific uremic arteriolopathy., Nigwekar SU,, Current opinion in nephrology and hypertension, 2015 Nov [PubMed PMID: 26371529]|
|||Sodium thiosulfate therapy for calcific uremic arteriolopathy., Nigwekar SU,Brunelli SM,Meade D,Wang W,Hymes J,Lacson E Jr,, Clinical journal of the American Society of Nephrology : CJASN, 2013 Jul [PubMed PMID: 23520041]|
|||Hyperbaric oxygen in the treatment of calciphylaxis: A case series and literature review., An J,Devaney B,Ooi KY,Ford S,Frawley G,Menahem S,, Nephrology (Carlton, Vic.), 2015 Jul [PubMed PMID: 25707425]|
|||Calcific uraemic arteriolopathy (calciphylaxis): data from a large nationwide registry., Brandenburg VM,Kramann R,Rothe H,Kaesler N,Korbiel J,Specht P,Schmitz S,Krüger T,Floege J,Ketteler M,, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2017 Jan 1 [PubMed PMID: 26908770]|
|||Early clinical presentations and progression of calciphylaxis., Ghosh T,Winchester DS,Davis MDP,El-Azhary R,Comfere NI,, International journal of dermatology, 2017 Aug [PubMed PMID: 28436018]|
|||We Do Too Many Parathyroidectomies for Calciphylaxis., Nigwekar SU,Sprague SM,, Seminars in dialysis, 2016 Jul [PubMed PMID: 27082830]|
|||A Nationally Representative Study of Calcific Uremic Arteriolopathy Risk Factors., Nigwekar SU,Zhao S,Wenger J,Hymes JL,Maddux FW,Thadhani RI,Chan KE,, Journal of the American Society of Nephrology : JASN, 2016 Nov [PubMed PMID: 27080977]|
|||Calcific Uremic Arteriolopathy Revisited., Jovanovich A,Chonchol M,, Journal of the American Society of Nephrology : JASN, 2016 Nov [PubMed PMID: 27225039]|
|||Quantifying a rare disease in administrative data: the example of calciphylaxis., Nigwekar SU,Solid CA,Ankers E,Malhotra R,Eggert W,Turchin A,Thadhani RI,Herzog CA,, Journal of general internal medicine, 2014 Aug [PubMed PMID: 25029979]|
|||Serum levels of the fetuin-mineral complex correlate with artery calcification in the rat., Price PA,Williamson MK,Nguyen TM,Than TN,, The Journal of biological chemistry, 2004 Jan 16 [PubMed PMID: 14578360]|